Table 3 Scores of QOL in paired 95 patients at two time points
Outcomes | Baseline | Follow-up | P values |
|---|---|---|---|
QLQ-C30 | |||
 Physical functioning | 77.2 ± 17.2 | 74.1 ± 14.8 | 0.039 |
 Role functioning | 75.6 ± 27.5 | 69.6 ± 25.5 | 0.047 |
 Cognitive functioning | 78.4 ± 18.2 | 70.9 ± 22.0 | 0.002 |
 Emotional functioning | 73.0 ± 18.0 | 75.3 ± 17.2 | 0.237 |
 Social functioning | 63.2 ± 27.0 | 58.6 ± 24.5 | 0.132 |
 Global health | 54.2 ± 21.7 | 57.0 ± 18.1 | 0.300 |
 Financial difficulties | 49.5 ± 33.6 | 51.9 ± 32.5 | 0.365 |
 Fatigue | 38.4 ± 19.1 | 37.3 ± 17.5 | 0.638 |
 Nausea and vomiting | 9.1 ± 15.1 | 15.1 ± 18.0 | 0.003 |
 Pain | 22.5 ± 24.2 | 20.0 ± 15.1 | 0.367 |
 Dyspnea | 15.1 ± 21.6 | 17.5 ± 21.1 | 0.320 |
 Insomnia | 34.4 ± 19.1 | 29.4 ± 26.2 | 0.001 |
 Appetite loss | 18.9 ± 23.1 | 26.3 ± 24.3 | 0.033 |
 Constipation | 20.0 ± 31.7 | 20.4 ± 27.6 | 0.912 |
 Diarrhea | 7.4 ± 13.9 | 6.3 ± 14.0 | 0.580 |
QLQ-OV28 | |||
 Body image | 48.4 ± 24.6 | 45.6 ± 28.4 | 0.386 |
 Sexual functioning | 3.5 ± 8.7 | 3.0 ± 9.7 | 0.567 |
 Attitude toward disease/treatment | 60.4 ± 26.6 | 55.9 ± 27.2 | 0.110 |
 Abdominal symptoms | 19.6 ± 16.1 | 17.7 ± 14.2 | 0.287 |
 Neurological symptoms | 30.2 ± 22.0 | 31.2 ± 21.9 | 0.681 |
 Menopausal symptoms | 15.1 ± 17.5 | 17.9 ± 17.0 | 0.138 |
 Other side-effects | 15.5 ± 13.1 | 18.8 ± 13.3 | 0.029 |